What is William Blair’s Forecast for Amedisys Q1 Earnings?

Amedisys, Inc. (NASDAQ:AMED) – Analysts at William Blair issued their Q1 2026 earnings per share estimates for Amedisys in a research report issued on Tuesday, July 29th. William Blair analyst M. Larew expects that the health services provider will post earnings of $0.91 per share for the quarter. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, July 29th. The health services provider reported $1.54 EPS for the quarter, beating the consensus estimate of $1.39 by $0.15. Amedisys had a return on equity of 12.91% and a net margin of 3.56%. The business had revenue of $621.86 million for the quarter, compared to the consensus estimate of $614.61 million. During the same period in the previous year, the business earned $0.98 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis.

Several other equities analysts also recently commented on AMED. Royal Bank Of Canada restated an “outperform” rating and issued a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Wall Street Zen downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 24th.

Amedisys Price Performance

Shares of Amedisys stock opened at $98.51 on Friday. The stock’s 50-day simple moving average is $96.75 and its 200-day simple moving average is $94.18. Amedisys has a 52 week low of $82.15 and a 52 week high of $99.00. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of 38.33, a PEG ratio of 1.33 and a beta of 0.89. The company has a quick ratio of 1.29, a current ratio of 1.36 and a debt-to-equity ratio of 0.26.

Institutional Investors Weigh In On Amedisys

A number of hedge funds have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Amedisys in the second quarter worth about $834,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Amedisys in the second quarter worth about $32,000. First Citizens Bank & Trust Co. purchased a new stake in Amedisys during the second quarter valued at approximately $443,000. Chicago Partners Investment Group LLC purchased a new stake in Amedisys during the second quarter valued at approximately $243,000. Finally, Cannon Global Investment Management LLC raised its position in Amedisys by 49.2% during the second quarter. Cannon Global Investment Management LLC now owns 5,670 shares of the health services provider’s stock valued at $558,000 after purchasing an additional 1,870 shares during the period. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.